The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
But ultimately the the goal was to evaluate the utility of that estrogen-based hormone therapy for reduced risk of cardiovascular disease. and they stopped one of the trials early because they saw that, you know, it wasn't reducing risk and that perhaps it was going in the other direction and so they couldn't ethically continue the trial.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.